Dra. María Natalia Gandur Quiroga
@nataliagandur
Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte Views Mine
🗣️ “When cure is possible, but toxicity is probable… what matters most?” Let’s talk adjuvant IO in early ccRCC 👇 @OncoAlert @gbanna74 @ravikanesvaran @PGrivasMDPhD @neerajaiims @AlbigesL @montypal @drenriquegrande @DrYukselUrun #IUCS25 #KidneyCancer #GUonc #Immunotherapy
🔵 IUCS25 Clinical Case Poll @OncoAlert @gbanna74 @ravikanesvaran 👨⚕️ 67 y/o man, PS0 🧬 Grade 3 pT3a ccRCC 🚫 No sarcomatoid/rhabdoid features 🧠 Concerned about IO toxicity ❓What drives your adjuvant IO decision?
A warm invite to all of our GU Colleagues to attend IN PERSON OR ONLINE (HYBRID) To the International Urology Cancer Summit🇬🇧 in Portsmouth!! REGISTER HERE👉 buff.ly/ahAjiFj The International Urology Cancer Summit is a free, independent educational event for all…
Updated results from KEYNOTE-B61: First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows: ✅ ORR 51% ✅ CR in 8.2% ✅ Median DOR 19.5 mo A promising option for nccRCC. #oncology #kidneycancer @EUplatinum @AlbigesL @OncoAlert @Uromigos pubmed.ncbi.nlm.nih.gov/40707309/
Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 sciencedirect.com/science/articl… The Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where…
2/ Our friend @nataliagandur with insights from the #PROFIT trial: x.com/nataliagandur/…
🔵 🆕️ 2025 insights from the #PROFIT trial in #ProstateCancer Focusing on intermediate-risk patients treated with RT: 📌 1. Patient-reported outcomes (Sanmamed et al.) 🔹️ Hypofractionation (60 Gy/20 fx) vs. Conventional (78 Gy/39 fx) 🔹️Comparable urinary QoL 🔹️ Less…
🚨 The OncoAlert WEEKLY RoundUp is HERE! (July 18–24, 2025) Your essential update in 🫁🧬💪☢️🧠💖 📍 Register now: 🔗 OncoAlert360.com or 🔗 oncoalert.m-pages.com/nhMpwe/oncoale 🔍 This week in cancer science: 🫁 FLAURA2 Update in #NSCLC 🏃♂️ Exercise & Outcomes in #ProstateCancer ⚔️…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…
Exercise in patients with metastatic prostate cancer: A comprehensive review cancertreatmentreviews.com/article/S0305-… Physical activity🏃 and structured exercise have been shown to significantly improve quality of life in #ProstateCancer (PC) patients, particularly by alleviating side effects…
I had the pleasure of meeting w/ @ASCO staff last week in which I introduced my presidential theme for 2025-2026: "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide." Excited to roll this out over the course of the year, and of course, at #ASCO26!
Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort Study sciencedirect.com/science/articl… This multicenter retrospective cohort study evaluated the safety of MRI-driven active surveillance…
The @OncoAlert 🚨 @VJOncology JOURNAL CLUB This week we have the pleasure to bring you @Silke_Gillessen 🇨🇭of Medical Oncologist, Oncology Institute of Southern Switzerland and @APCCC_Lugano Discussing: Metformin for patients with metastatic #ProstateCancer starting androgen…
News From Industry/ FLAURA2 Update Source AstraZeneca buff.ly/IxqmQjH Long-term follow-up from the Phase III FLAURA2 trial confirms that combining osimertinib with platinum-based chemotherapy and pemetrexed significantly improves overall survival in patients with…
Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis europeanurology.com/article/S0302-… Meta-analysis of 19 observational studies involving up to 118,830 patients with clinically localized #ProstateCancer found that treatment with…
Did you miss the #GUARDSymposium2025 ? We Have you covered🚨, here are some Great Presentations from Some of the World's TOP GU Oncologists📺 ⭐️What biomarkers are necessary in advanced urothelial carcinoma? Dr. Yves Allory Guard Symposium25 youtu.be/cwrUNwkqw3o?si… ⭐️Andrea…
🔵 🆕️ 2025 insights from the #PROFIT trial in #ProstateCancer Focusing on intermediate-risk patients treated with RT: 📌 1. Patient-reported outcomes (Sanmamed et al.) 🔹️ Hypofractionation (60 Gy/20 fx) vs. Conventional (78 Gy/39 fx) 🔹️Comparable urinary QoL 🔹️ Less…
💯— missing #KCRS25 this year but I believe #kidneycancer is curable and we absolutely need to work together to cure more of our patients. @Uromigos @kidneycan @kcCURE @KidneyCancer
💡 Great review of progress over the last 10 years in 1st-line metastatic RCC 🚀 and a call from David McDermott to work together to cure more patients with kidney cancer 🤝 @kidneycan #KCRS25 #rcc #kidneycancer
🚨 This week on the OncoAlert RoundUp! 🎯 Unmissable updates from July 11–17 🔥 ➡️ #TALAPRO2 in 🔵 #ProstateCancer ➡️ Geriatric 👴 Assessment in Oncology ➡️ Molecular insights in 🟢 #KidneyCancer (non-ccRCC) ➡️ #POSITIVETrial in 🎗 #BreastCancer ➡️ Mutational forces in 🫁…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…
Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer @Annals_Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant #ProstateCancer annalsofoncology.org/article/S0923-… The final analysis of the…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…